A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site

Although aminergic GPCRs are the target for ~25% of approved drugs, developing subtype selective drugs is a major challenge due to the high sequence conservation at their orthosteric binding site. Bitopic ligands are covalently joined orthosteric and allosteric pharmacophores with the potential to boost receptor selectivity and improve current medications by reducing off-target side effects. However, the lack of structural information on their binding mode impedes rational design. Here we determine the cryo-EM structure of the hD<sub>3</sub>R:Gα<sub>O</sub>βγ complex bound to the D<sub>3</sub>R selective bitopic agonist FOB02-04A. Structural, functional and computational analyses provide insights into its binding mode and point to a new TM2-ECL1-TM1 region, which requires the N-terminal ordering of TM1, as a major determinant of subtype selectivity in aminergic GPCRs. This region is underexploited in drug development, expands the established secondary binding pocket in aminergic GPCRs and could potentially be used to design novel and subtype selective drugs.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2024-09-05
DOI
https://doi.org/10.1038/s41467-024-51993-4
Citations
11
Primary Topic
Receptor Mechanisms and Signaling
Type
article
Field-Weighted Citation Impact
2.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site

Javier García‐Nafría, Alessandro Bonifazi, Vsevolod Katritch, Sandra Arroyo‐Urea et al.
11 citations
Nature Communications
Receptor Mechanisms and Signaling
2.57
article

A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site

Javier García‐Nafría, Alessandro Bonifazi, Vsevolod Katritch, Sandra Arroyo‐Urea, Jordy Homing Lam, Ángela Carrión-Antolí, Antonina L. Nazarova, Francisco O. Battiti, Amy Hauck Newman
article en
11 citations

Abstract

Although aminergic GPCRs are the target for ~25% of approved drugs, developing subtype selective drugs is a major challenge due to the high sequence conservation at their orthosteric binding site. Bitopic ligands are covalently joined orthosteric and allosteric pharmacophores with the potential to boost receptor selectivity and improve current medications by reducing off-target side effects. However, the lack of structural information on their binding mode impedes rational design. Here we determine the cryo-EM structure of the hD<sub>3</sub>R:Gα<sub>O</sub>βγ complex bound to the D<sub>3</sub>R selective bitopic agonist FOB02-04A. Structural, functional and computational analyses provide insights into its binding mode and point to a new TM2-ECL1-TM1 region, which requires the N-terminal ordering of TM1, as a major determinant of subtype selectivity in aminergic GPCRs. This region is underexploited in drug development, expands the established secondary binding pocket in aminergic GPCRs and could potentially be used to design novel and subtype selective drugs.

Nature CommunicationsVol. 15(1)
University of Southern California (US), National Institute on Drug Abuse (US), Universidad de Zaragoza (ES), Convergent Science (United States) (US)
University of Southern California, European Commission, European Synchrotron Radiation Facility, Ministerio de Educación, Cultura y Deporte, Universidad de Zaragoza, European Regional Development Fund
Openalex Percentile: Top 10%
Receptor Mechanisms and Signaling
2.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.